Immunotech Biopharm Ltd (HK:6978) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Immunotech Biopharm Ltd has announced that foreign ownership restrictions on its partner Yongtai Ruike have been relaxed, allowing Beijing Yongtai to acquire full equity interest in the gene therapy business. The company plans to complete the equity transfer by December 2024, with no expected impact on its overall business operations and financial health. This strategic move is set to streamline operations and retain economic benefits from Yongtai Ruike.
For further insights into HK:6978 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- ‘Time to Jump Ship,’ Says Investor About MicroStrategy Stock
- Nvidia and Microsoft: Why This Top Investment Firm Decided to Dump Shares
- Wells Fargo (NYSE:WFC) Departs Philadelphia Sports Arena
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
